GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kiniksa Pharmaceuticals International PLC (NAS:KNSA) » Definitions » Margin of Safety % (DCF FCF Based)

KNSA (Kiniksa Pharmaceuticals International) Margin of Safety % (DCF FCF Based) : N/A (As of Apr. 04, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Kiniksa Pharmaceuticals International Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Kiniksa Pharmaceuticals International's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Kiniksa Pharmaceuticals International's Margin of Safety % (DCF FCF Based)

For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kiniksa Pharmaceuticals International's Margin of Safety % (DCF FCF Based) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Kiniksa Pharmaceuticals International's Margin of Safety % (DCF FCF Based) falls into.


;
;

Kiniksa Pharmaceuticals International Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Kiniksa Pharmaceuticals International's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiniksa Pharmaceuticals International Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kiniksa Pharmaceuticals International PLC (NAS:KNSA) » Definitions » Margin of Safety % (DCF FCF Based)
Comparable Companies
DVAX BCRX SUPN NDOI ANIP AMPH PCRX BGM NIKA COLL ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
N/A
Address
23 Old Bond Street, Floor 3, London, GBR, W1S 4PZ
Website
https://www.kiniksa.com
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Executives
Mark Ragosa officer: Interim CFO C/O KINIKSA PHARMACEUTICALS CORP., 100 HAYDEN AVENUE, LEXINGTON MA 02421
Michael R Megna officer: Chief Accounting Officer 1050 HINGHAM STREET, ROCKLAND MA 02370
Eben Tessari officer: Chief Business Officer C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Sanj K Patel director, 10 percent owner, officer: Chairman & CEO C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Ross Moat officer: Group VP & Rilonacept GM C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
John Paolini officer: Chief Medical Officer C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Barry D Quart director C/O INTRABIOTICS PHARMACEUTICALS INC, 1009 OAK HILL ROAD, SUITE 201, LAFAYETTE CA 94549
Felix Baker director BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker director BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Arian Pano officer: Chief Clinical Dev. Officer C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Thomas W. Beetham 10 percent owner, officer: Chief Legal Officer C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
G Bradley Cole director 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063